Sangamo Therapeutics
Richmond, California, United States · Biotechnology, Genetics, Health Care · 271 employees
Sangamo Therapeutics uses science to develop transformative medicines for patients with serious genetic diseases. As pioneers in gene-based therapeutic development, the company’s scientists lead in discovery, research, and innovation, including conducting the first-ever in vivo human genome editing studies now underway in clinical trials.
Funding history
- Funding Round — $16.5M — Feb 2026
Recent signals
- Feb 04, 2026: Raised $16.5M
- Feb 03, 2026: SEC 8-K (1.01): On February 3, 2026, Sangamo Therapeutics, Inc. entered into an Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC for the sale of 35,190,292 shares of common stock and pre-funded warrants to purchase 17,787,033 shares of common stock, along with warrants to purchase an additional 52,977,325 shares. The combined offering price for each share and accompanying Purchase Warrant is set at $0.4719. This transaction is a significant move for Sangamo, expanding its capital base and enhancing its ability to fund ongoing research and development activities.
- Sep 30, 2025: Sangamo Therapeutics Appoints Nikunj Jain as Principal Accounting Officer
- Dec 15, 2024: Sangamo Therapeutics partners with Genentech for genomic medicines development
- Oct 22, 2024: Launched Sangamo Therapeutics Launches ST-920, a Gene Therapy for Fabry Disease Following FDA's Accelerated Approval Pathway Agreement.
- Aug 06, 2024: Sangamo Therapeutics Announces License Agreement with Genentech for Developing Genomic Medicines
See plans & pricing → Track Sangamo Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.